[EN] SOMATOSTATIN RECEPTOR 1 AND/OR 4 SELECTIVE AGONISTS AND ANTAGONISTS [FR] AGONISTES ET ANTAGONISTES SELECTIFS DU RECEPTEUR DE LA SOMATOSTATINE 1 ET/OU 4
SOMATOSTATIN RECEPTOR 1 AND/OR 4 SELECTIVE AGONISTS AND ANTAGONISTS
申请人:Wurster, Siegfried
公开号:EP1675824B1
公开(公告)日:2010-09-29
Somatostatin receptor 1 and/or 4 selective agonists and antagonists
申请人:Tomperi Jussi
公开号:US20070129422A1
公开(公告)日:2007-06-07
The invention relates to (hetero)arylsulfonylamino based peptidomimetics of formula (I), wherein R1, R2, R3, A, B, D, Q, k and n are defined as disclosed, or a pharmaceutically acceptable salt or ester thereof. Compounds of formula (I) possess high affinity and selectivity for the somatostatin receptor subtypes SSTR1 and/or SSTR4 and can be used for the treatment or diagnosis of diseases or conditions wherein an interaction with SSTR1 and/or SSTR4 is indicated to be useful.
Somatostatin Receptor 1 and/or 4 Selective Agonists and Antagonists
申请人:Tomperi Jussi
公开号:US20100004339A1
公开(公告)日:2010-01-07
The invention relates to (hetero)arylsulfonylamino based peptidomimetics of formula (I), wherein R1, R2, R3, A, B, D, Q, k and n are defined as disclosed, or a pharmaceutically acceptable salt or ester thereof. Compounds of formula (I) possess high affinity and selectivity for the somatostatin receptor subtypes SSTR1 and/or SSTR4 and can be used for the treatment or diagnosis of diseases or conditions wherein an interaction with SSTR1 and/or SSTR4 is indicated to be useful.
US7741362B2
申请人:——
公开号:US7741362B2
公开(公告)日:2010-06-22
[EN] SOMATOSTATIN RECEPTOR 1 AND/OR 4 SELECTIVE AGONISTS AND ANTAGONISTS<br/>[FR] AGONISTES ET ANTAGONISTES SELECTIFS DU RECEPTEUR DE LA SOMATOSTATINE 1 ET/OU 4
申请人:JUVANTIA PHARMA LTD OY
公开号:WO2005033069A1
公开(公告)日:2005-04-14
The invention relates to (hetero)arylsulfonylamino based peptidomimetics of formula (I), wherein R1, R2, R3, A, B, D, Q, k and n are defined as disclosed, or a pharmaceutically acceptable salt or ester thereof. Compounds of formula (I) possess high affinity and selectivity for the somatostatin receptor subtypes SSTR1 and/or SSTR4 and can be used for the treatment or diagnosis of diseases or conditions wherein an interaction with SSTR1 and/or SSTR4 is indicated to be useful.